This announcement contains inside
information as stipulated under the UK version of the
Market Abuse Regulation No 596/2014 which is part of English law by
virtue of the European (Withdrawal) Act 2018, as amended. On
publication of this announcement via a regulatory information
service, this information is considered to be in the public
domain.
23 October
2024
EDX Medical Group
plc
AQSE: EDX
("EDX Medical" or
the "Company")
Strategic investment via
Placing of Shares
CAMBRIDGE,
UK: EDX Medical Group plc, which
develops innovative digital diagnostic products and services
supporting personalised treatments for cancer, heart disease and
infectious diseases, announces that the Company has received a
strategic investment of £300,000 from a private
investor via the placing of 2,727,272 new ordinary shares of 1p
each ("the Placing Shares") in the Company at a price of 11p per
share ("the Placing Price").
The investment in the Company at a premium of
22 % on the current market share price will be used to support the
expansion of EDX Medical's capabilities and operations.
The investor is a highly experienced healthcare
investor based in Saudi Arabia and has been assisted in the Placing
by Capital Plus Partners, London.
An application has been made for the Placing
Shares to be admitted to trading on the AQSE Growth Market and
admission is expected to become effective on October 25,
2024.
Professor Sir Chris Evans, OBE,
founder of EDX Medical, commented: "We are
delighted that another high net worth, experienced healthcare
investor with a track record in successful medical ventures has
chosen to support EDX Medical. This investor's extensive network of
healthcare contacts in the Gulf is also of considerable importance
to the marketing of our new products in that region."
Dr Mike
Hudson, Chief Executive Officer of EDX Medical,
commented: "This investment is another
declaration of support in our strategy of developing and providing
class-leading diagnostic solutions that will help health
professionals achieve better outcomes for patients."
Total Voting
Rights
In accordance with the Financial Conduct
Authority's Disclosure and Transparency Rules, the Company hereby
announces that following the Placing, it will have 350,084,848
Ordinary Shares in issue, each share carrying the right to one
vote.
The above figure of 350, 084,848 Ordinary
Shares may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
The directors of EDX Medical accept
responsibility for the contents of this announcement.
Contacts:
EDX Medical
Group plc
|
|
Dr Mike Hudson (Chief Executive
Officer)
|
+44 (0)7812 345 301
|
Oberon
Capital
|
|
Nick Lovering (Corporate
Adviser)
Adam Pollock (Corporate
Broking)
Mike Seabrook (Corporate
Broking)
|
+44 (0)20 3179 5300
|
Capital Plus
Partners
|
|
Keith Swann
|
+44 (0)203 821 6169
KS@capplus.co.uk
|
Media House
International
|
|
Ramsay Smith
Gary McQueen
|
+44 (0)7788 414856
ramsay@mediahouse.co.uk
+ 44 (0)7834 694609
gary@mediahouse.co.uk
|
IFC Advisory
(Investor Relations)
|
|
Tim Metcalfe
Graham Herring
|
+44 (0) 203 934 6630
|
Notes for
Editors:
About EDX
Medical Group
EDX Medical Group plc is listed on
the Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by
Professor Sir Christopher Evans, OBE, a medical and life
sciences entrepreneur with more than 30 years of experience,
together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic
solutions combining advanced biological and digital technologies,
EDX Medical seeks to cost effectively improve the detection and
characterisation of disease in order to personalise treatment in a
timely fashion. Early disease detection and biologically-based
personal treatment optimisation is considered to be the most
impactful way of reducing deaths and lowering the cost of
healthcare globally.
EDX Medical Group provides doctors,
hospitals and insurers/payers with access to a portfolio of the
best clinical diagnostics products and services. The Company
operates its own facilities in Cambridge and Oxford,
UK, and has strategic product and technology partnerships with
organisations such as Thermo Fisher EMEA Ltd, a world leader
in supplying life sciences solutions and services.
EDX Medical conducts product development,
validation and distribution to ISO 13485 and provides PCR and
genomic sequencing services accredited to ISO 15189 by
the United Kingdom Accreditation
Service (UKAS).